UroGen Pharma URGN Jelmyto — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: UroGen Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about UroGen Pharma's jelmyto — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is UroGen Pharma's jelmyto — revenue?
- UroGen Pharma (URGN) reported jelmyto — revenue of $21.71M in Q1 2026.
- How has UroGen Pharma's jelmyto — revenue changed year-over-year?
- UroGen Pharma's jelmyto — revenue increased by 7.2% year-over-year, from $20.25M to $21.71M.
- What is the long-term trend for UroGen Pharma's jelmyto — revenue?
- Over 4 years (2021 to 2025), UroGen Pharma's jelmyto — revenue has grown at a 18.3% compound annual growth rate (CAGR), from $48.04M to $93.99M.
- What does jelmyto — revenue mean?
- This metric represents the gross revenue generated from the sale of a specific product or service, net of any sales-related taxes collected on behalf of government authorities. It serves as the primary indicator of commercial adoption and market demand for the product segment. By excluding taxes, it provides a standardized view of the top-line performance that is comparable across different jurisdictions and reporting periods.